| Nov 25 | Feb 26 | May 26 | Aug 26 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Buy | — | 4 | 1 | — | — | 2 | 1 | — | — | — | — | 2 |
| Sell | — | — | — | — | — | — | 1 | — | — | — | — | — |
| total | individual payouts | |
|---|---|---|
| 2028 | ‡‡‡‡ |
|
| 2027 | ‡‡‡‡ |
|
| 2026 | ‡‡‡‡ |
|
| 2025 | ‡‡‡‡ |
|
| 2024 | ‡‡‡‡ |
|
| 2023 | ‡‡‡‡ |
|
| 2021 | 0.72 |
—
—
—
—
|
| 2020 | 0.68 |
—
—
—
—
|
| 2019 | 0.68 |
—
—
—
—
|
| 2018 | 0.68 |
—
—
—
—
|
| 2017 | 0.65 |
—
—
—
—
|
| 2016 | 0.48 |
—
—
—
|
| 2023 | 2024 | 2025 | Q'26 | |
|---|---|---|---|---|
| Cash | 152.79 | 105.78 | 42.63 | 41.19 |
| Receivables | 132.21 | 171.55 | 230.42 | 215.30 |
| Inventory | 31.38 | 24.30 | 43.51 | 42.37 |
| Other | 27.23 | 20.47 | 61.39 | 17.80 |
| 343.60 | 322.10 | 377.95 | 316.66 |
| 2023 | 2024 | 2025 | Q'26 | |
|---|---|---|---|---|
| Payables | 47.44 | 54.44 | 69.62 | 81.93 |
| ST’ Debt | 61.88 | 82.50 | — | — |
| Other | — | 6.23 | — | 5.44 |
| 274.91 | 352.42 | 359.92 | 361.73 |
| 10y | 5y | 3y | |
| Sales | — | — | ‡‡‡‡‡ |
| Cash Flow | — | — | ‡‡‡‡‡ |
| Earnings | — | — | ‡‡‡‡‡ |
| Book Value | — | — | ‡‡‡‡‡ |
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | 285.93 | 405.96 | — | — |
—
|
| ’25 | 226.77 | 288.52 | 272.56 | 387.54 |
1,175.39
|
| ’24 | 239.16 | 239.99 | 255.54 | 234.94 |
969.63
|
| ’23 | 192.17 | 166.92 | 175.39 | 227.83 |
762.31
|
| ’22 | — | — | 295.74 | — |
937.41
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | 170.31 | 153.65 | — | — |
—
|
| ’25 | 142.52 | 130.14 | 105.55 | 128.75 |
506.96
|
| ’24 | 143.95 | 116.83 | 110.85 | 133.66 |
505.29
|
| ’23 | 147.15 | 128.00 | 106.82 | 109.78 |
491.74
|
| ’22 | — | — | 398.30 | 155.24 |
553.54
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | 111.75 | 58.94 | — | — |
—
|
| ’25 | 93.81 | 67.83 | 49.21 | 30.30 |
241.16
|
| ’24 | 90.38 | 86.40 | 62.77 | 85.48 |
325.03
|
| ’23 | 64.69 | 23.11 | 36.89 | 55.59 |
180.28
|
| ’22 | — | — | 234.36 | 80.39 |
314.74
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (0.21) | 0.58 | — | — |
—
|
| ’25 | 0.14 | 0.76 | (0.28) | 0.50 |
1.09
|
| ’24 | 0.44 | 0.42 | 0.70 | 0.34 |
1.90
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | 14.40 | 14.46 | 10.93 | — | — | — |
Low Price
|
| — | — | — | — | — | — | — | 19.20 | 21.19 | 19.00 | — | — | — |
High Price
|
| — | — | — | — | — | — | — | 444 | 505 | 840 | — | — | — |
Employees
|
| — | — | — | — | — | ‡‡‡ | 0.00 | 1.72 | 1.92 | 1.40 | — | — | — |
Revenue/Emp
|
| — | — | — | — | — | ‡‡‡‡‡ | 937.41 | 762.31 | 969.63 | 1,175.39 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Revenue
|
| — | — | — | — | — | ‡‡‡‡‡ | 72.99% | 72.98% | 66.88% | 62.41% | — | — | — |
Gross Margin
|
| — | — | — | — | — | ‡‡‡‡‡ | 516.84 | 346.56 | 185.18 | 142.98 | — | — | — |
EBT
|
| — | — | — | — | — | ‡‡‡‡‡ | 55.13% | 45.46% | 19.10% | 12.16% | ‡‡‡ | ‡‡‡ | ‡‡‡ |
EBT Margin
|
| — | — | — | — | — | ‡‡‡‡‡ | 516.84 | 346.56 | 185.18 | 142.98 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Net Income
|
| — | — | — | — | — | ‡‡‡‡‡ | 88.96 | 139.57 | 278.36 | 297.91 | — | — | — |
Depreciation
|
| — | — | — | — | — | ‡‡‡ | 0.00 | 8.03 | 9.94 | 8.94 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Revenue/Sh
|
| — | — | — | — | — | — | — | 0.72 | 1.90 | 1.09 | ‡‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ |
Earnings/Sh
|
| — | — | — | — | — | ‡‡‡ | 0.00 | 5.18 | 5.18 | 3.86 | — | — | — |
Cash Flow/Sh
|
| — | — | — | — | — | ‡‡‡ | 0.00 | (3.28) | (1.85) | (2.02) | ‡‡‡ | ‡‡‡ | ‡‡‡ |
Capex/Sh
|
| — | — | — | — | — | ‡‡‡ | 0.00 | 1.90 | 3.33 | 1.83 | — | — | — |
Free CF/Sh
|
| — | — | — | — | — | ‡‡‡ | 0.00 | 12.56 | 12.29 | 15.13 | — | — | — |
Book Value/Sh
|
| — | — | — | — | — | — | — | 94.91 | 97.59 | 131.46 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Shares
|
| — | — | — | — | — | ‡‡‡‡‡ | 6.56 | 6.56 | 9.04 | 9.86 | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡ |
PE Ratio
|
| — | — | — | — | — | ‡‡‡‡‡ | 2.10 | 1.98 | 1.73 | 1.23 | ‡‡‡ | ‡‡‡ | ‡‡‡ |
PS Ratio
|
| — | — | — | — | — | ‡‡‡‡‡ | 2.27 | 1.27 | 1.40 | 0.73 | ‡‡‡ | ‡‡‡ | ‡‡‡ |
PB Ratio
|
| — | — | — | — | — | ‡‡‡‡‡ | 2.15 | 2.84 | 2.39 | 2.24 | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ |
EV/Sales
|
| — | — | — | — | — | ‡‡‡‡‡ | 8.70 | 12.00 | 7.14 | 10.93 | — | — | — |
EV/FCF
|
| — | — | — | — | — | ‡‡‡‡‡ | 553.54 | 491.74 | 505.29 | 506.96 | ‡‡‡ | ‡‡‡ | ‡‡‡ |
Op' Cash Flow
|
| — | — | — | — | — | ‡‡‡‡‡ | (238.80) | (311.46) | (180.27) | (265.80) | ‡‡‡‡‡ | — | — |
Capex
|
| — | — | — | — | — | ‡‡‡‡‡ | 314.74 | 180.28 | 325.03 | 241.16 | — | — | — |
FCF
|
| — | — | — | — | — | — | 33.59 | 68.69 | (30.32) | 18.03 | — | — | — |
Working Cap'
|
| — | — | — | — | — | — | 84.90 | 807.02 | 751.28 | 1,144.06 | — | — | — |
Total Debt
|
| — | — | — | — | — | — | 55.48 | 654.22 | 645.50 | 1,101.42 | — | — | — |
Net Debt
|
| — | — | — | — | — | ‡‡‡ | 593.23 | 1,191.72 | 1,199.05 | 1,989.39 | — | — | — |
Sh' Equity
|
| — | — | — | — | — | ‡‡‡ | 116.42% | 4.29% | 7.98% | 4.68% | — | — | — |
ROA
|
| — | — | — | — | — | ‡‡‡ | 50.33% | 12.16% | 9.86% | 4.95% | — | — | — |
ROIC
|
| — | — | — | — | — | ‡‡‡ | 0.00% | 7.68% | 15.49% | 8.97% | — | — | — |
ROE
|
Mach Natural Resources LP (MNR), a Permian Basin-focused MLP, has shown resilient revenue growth amid energy market volatility, surging 27% to $970 million in 2024 despite commodity cycles, with productivity metrics like revenue per employee climbing 12%. Strong free cash flow per share doubled to $3.33, supporting distributions even as profitability margins compressed to 19.1%, while gross margins held a competitive 66.9%. Trading at deep discounts—37-91% below analyst targets—with attractive EV/FCF of 7.1x and insider buying exceeding $10 million (no sells), MNR signals undervaluation reminiscent of past Permian rebounds.
Projections forecast revenue expansion to $1.46 billion by 2027, but a 73% share dilution risks per-share metrics, echoing 2014-2016 cycles where capex-funded growth later rewarded investors. Balance sheet strength, with ROE doubling to 15.5% and moderated capex, positions MNR for FCF yields amid Permian consolidation and LNG tailwinds.
Risks include OPEC+ dynamics, EV shifts, and recession fears, yet insider confidence and historical parallels suggest 40-90% upside potential over 12-24 months for patient allocators.
Keep track of companies that you follow and research.
Full access to our data with predictions and indicators that we calculate daily.
Full access to our screener with tons of custom values and customizable email notifications.
Excel export of financials and screeners you define and save.